Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 330.53 USD 0.66% Market Closed
Market Cap: 9.3B USD
Have any thoughts about
Bio Rad Laboratories Inc?
Write Note

Bio Rad Laboratories Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bio Rad Laboratories Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Bio Rad Laboratories Inc
NYSE:BIO
Total Current Liabilities
$497.9m
CAGR 3-Years
-8%
CAGR 5-Years
3%
CAGR 10-Years
0%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Current Liabilities
$14.6B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Current Liabilities
$7.3B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Total Current Liabilities
$1.2B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Total Current Liabilities
$1.9B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Total Current Liabilities
$7B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Bio Rad Laboratories Inc
Glance View

Market Cap
9.3B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Rad Laboratories Inc. began its journey in 1952 and has since positioned itself as a formidable player in the life sciences and clinical diagnostics sectors. Founded by David and Alice Schwartz, the company thrived on the burgeoning interest in biological research, carving a niche by supplying essential products to scientists and healthcare professionals. With its headquarters in Hercules, California, Bio-Rad has continually developed a suite of innovative solutions that cater to both academic research and the intricate needs of clinical diagnostics, paving its way to becoming a global leader. Their operations are distinctly bifurcated: Life Science, which focuses on products for gene expression, protein purification, and food safety, and Clinical Diagnostics, offering tools for blood testing and diabetes monitoring. The core of Bio-Rad’s business model lies in its ability to design and manufacture advanced technological products that streamline laboratory processes, making research and diagnostics more efficient and reliable. The Life Science segment generates revenue by selling reagents, lab instruments, and software that facilitate various laboratory protocols and experiments, assisting scientists in their pursuit of breakthroughs in biotechnology and pharmaceutical development. Meanwhile, the Clinical Diagnostics segment garners earnings through the provision of innovative testing and analysis tools that enable accurate disease diagnosis, blood analysis, and quality control. Guided by a robust infrastructure of research and development, the company continuously adapts to the evolving demands of science and healthcare, maintaining its fiscal health while reinforcing its reputation as a trusted provider in the global market.

BIO Intrinsic Value
385.57 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Bio Rad Laboratories Inc's Total Current Liabilities?
Total Current Liabilities
497.9m USD

Based on the financial report for Sep 30, 2024, Bio Rad Laboratories Inc's Total Current Liabilities amounts to 497.9m USD.

What is Bio Rad Laboratories Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
0%

Over the last year, the Total Current Liabilities growth was -11%. The average annual Total Current Liabilities growth rates for Bio Rad Laboratories Inc have been -8% over the past three years , 3% over the past five years .

Back to Top